Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;87(2):399-400.
doi: 10.1016/j.jaad.2022.02.030. Epub 2022 Feb 23.

Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic review

Jordan Taylor Said  1 , Scott Andrew Elman  2 , Lourdes Maria Perez-Chada  2 , Carol Mita  3 , Joseph F Merola  4 , Nicole R LeBoeuf  5
Affiliations

Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic review

Jordan Taylor Said et al. J Am Acad Dermatol. 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Dr Merola is consultant and/or investigator for AbbVie, Aclaris, Almirall, Arena, Avotres, Biogen, Celgene, Dermavant, Eli Lilly, EMD Serono, Incyte, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals Inc, Sanofi, Sun Pharma, and UCB. Dr LeBoeuf is a consultant and has received honoraria from Bayer, Seattle Genetics, Sanofi, Silverback, and Synox Therapeutics, outside the submitted work. Authors Said, Mita, Dr Elman, and Dr Perez-Chada have no conflicts of interest to disclose.

References

    1. Phillips GS, Wu J, Hellmann MD, et al. Treatment Outcomes of Immune-Related Cutaneous Adverse Events. J Clin Oncol. Published online June 2019:JCO.18.02141. doi:10.1200/JCO.18.02141 - DOI - PMC - PubMed
    1. Nikolaou V, Sibaud V, Fattore D, et al. Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group. J Am Acad Dermatol. Published online 2021. doi:10.1016/j.jaad.2020.08.137 - DOI - PubMed
    1. Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines. JNCCN J Natl Compr Cancer Netw. 2020;18(3):231–241. doi:10.6004/jnccn.2020.0012 - DOI - PubMed
    1. Menter A, Gelfand JM, Connor C, et al. Joint AAD-NPF Guidelines Of Care For The Management Of Psoriasis With Systemic Non-Biological Therapies. Artical in press. J Am Acad Dermatol. Published online 2020.
    1. Klebanov N, Perez-Chada LM, Gupta S, Gottlieb AB, Merola JF. Low gene expression of TNF, IL17A, IL23A, and IL12B in tumors: a safety surrogate to predict cancer survival associated with biologic therapies. J Am Acad Dermatol. Published online 2020. doi:10.1016/j.jaad.2020.08.050 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances